Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
BAGE2 Biologics Sequence Review Report 2026: B melanoma antigen 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BAGE2 Biologics Sequence Review Report 2026: B melanoma antigen 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of BAGE2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BAGE3 Biologics Sequence Review Report 2026: B melanoma antigen 3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BAGE3 Biologics Sequence Review Report 2026: B melanoma antigen 3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of BAGE3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BCAP29 Biologics Sequence Review Report 2026: B-cell receptor-associated protein 29 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BCAP29 Biologics Sequence Review Report 2026: B-cell receptor-associated protein 29 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of BCAP29 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
AVPR1B Biologics Sequence Review Report 2026: Vasopressin V1b receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
AVPR1B Biologics Sequence Review Report 2026: Vasopressin V1b receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of AVPR1B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ATP6AP2 Biologics Sequence Review Report 2026: Renin receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ATP6AP2 Biologics Sequence Review Report 2026: Renin receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ATP6AP2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
AVPR1A Biologics Sequence Review Report 2026: Vasopressin V1a receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
AVPR1A Biologics Sequence Review Report 2026: Vasopressin V1a receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of AVPR1A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ASGR2 Biologics Sequence Review Report 2026: Asialoglycoprotein receptor 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ASGR2 Biologics Sequence Review Report 2026: Asialoglycoprotein receptor 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ASGR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ANTXR2 Biologics Sequence Review Report 2026: Anthrax toxin receptor 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ANTXR2 Biologics Sequence Review Report 2026: Anthrax toxin receptor 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ANTXR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ANTXR1 Biologics Sequence Review Report 2026: Anthrax toxin receptor 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ANTXR1 Biologics Sequence Review Report 2026: Anthrax toxin receptor 1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ANTXR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ANXA2R Biologics Sequence Review Report 2026: Annexin-2 receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ANXA2R Biologics Sequence Review Report 2026: Annexin-2 receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ANXA2R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
APLNR Biologics Sequence Review Report 2026: Apelin receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
APLNR Biologics Sequence Review Report 2026: Apelin receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of APLNR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ANKRD33 Biologics Sequence Review Report 2026: Photoreceptor ankyrin repeat protein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ANKRD33 Biologics Sequence Review Report 2026: Photoreceptor ankyrin repeat protein Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ANKRD33 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →